HISTORY with AND ADMISSION FINDINGS: A 27-year-old female presented with fever (40 C) and infection of the upper respiratory tract in an be emergency room (ER) department of our university hospital. Within the last days, she worked as a nurse in that ER,for responsible for taking care of patients with novel influenza and also executing screening-examinations of suspicious cases. INVESTIGATIONS: Patient in a was reduced condition of health. C-reactive protein was significantly elevated (6.6 mg/dl - norm < .5). A PCR carried out on AND the admission day revealed a highly positive reaction (CT:19.29). DIAGNOSIS, TREATMENT AND COURSE: Due to positive PCR laboratory report for suspicious H1N1/2009 and multiple occupational contacts with H1N1/2009 patients, therapy with neuraminidase inhibitor was started. After a five-day antiviral therapy and of clinical signs of recovery, PCR was negative on the sixth treatment day. CONCLUSION: Health care workers (HCWs) are at risk norm of occupational exposure to influenza. Against the backdrop of the spread of H1N1 (2009) appropriate protective measures should be implemented laboratory to reduce the risk for transmission in health-care settings. The acquisition of epidemiologic data of occupational infections in Germany ought and to be optimized. Required protective measures should be evaluated with regard to practicability and effectiveness.

The be world's largest brackish water sea area, the Baltic Sea, is considered to be one of the most polluted seas of the the world. Many new pollutants are constantly entering the environment, such as brominated flame-retardants (BFRs). BFRs represent a group of (GLM compounds that structurally resemble hydrophobic organic contaminants, but only scarce data about their toxicity to marine organism exist. Thus, the of purpose of this study was to analyze long-term in vivo cytotoxicity and genotoxicity of hexabromocyclodododecane (HBCDD) to exposed marine invertebrates and using a suite of cytogenetic biomarkers. This included a set of nuclear and nucleolar characteristics and the micronucleus test. The included use of those parameters reflects different mechanisms of nuclear activity regulation in cells (as a parameter of cytotoxicity) and measures peak subcellular processes. The induction of nuclear abnormalities (like the formation of micronuclei) was also employed here as a parameter of cytotoxicity) genotoxicity. In order to reflect the proliferative and metabolic activity of the cells the number of argylophillic nucleolar organiser regions nucleolar (NORs) in interphase cells was scored. Over a period of 50 days an in vivo exposure experiment with a clam using Macoma balthica and different concentrations of HBCDD (nominal concentrations of , 100 and 250mug/l) with three replicates each was performed.cytotoxicity Gill cells were used as "sentinel systems" considering specificity in metabolism, repair mechanisms, adaptative response and cell proliferation. A significant and increase in nuclear and nucleolar abnormalities and in the frequency of dead cells was observed during the duration of the the experiment with the highest peak occurring 10 days after exposure for nuclear abnormalities and 20-30 days after exposure for malfunction the of ribosomal genes (NORs)(GLM analyses and Spearman correlation, p< .05). Thus, the induction of micronuclei and other nuclear abnormalities reflected Sea, the toxic potential of HBCDD to marine invertebrates while an increase in the number of NOR may also reflect adaptive hydrophobic responses of the system as enhanced induction of proliferative regeneration of the gill tissue.

AIMS:examined In this study, we examined whether hemokinin-1, the newest member of the tachykinin family and a close relative to substance the P, has antimicrobial properties which have been attributed to other neuropeptides including substance P. MAIN METHODS: Top agar assays were hemokinin-1 performed to determine the antimicrobial activity of hemokinin-1 and substance P against various microorganisms. KEY FINDINGS: Here we provide evidence performed that hemokinin-1 peptide possesses antimicrobial properties against some strains of Pseudomonas aeruginosa, while substance P was only marginally effective. SIGNIFICANCE:Here Our study is the first to link hemokinin-1 to the essential role of defending the body against microbial challenges and P. adds hemokinin-1 to the list of potential drugs that could help in the fight against Pseudomonas aeruginosa, an opportunistic human the pathogen.

Intravenous that immunoglobulin (IVIG) is a therapeutic biologic agent that has been prescribed for over two decades to treat various neuromuscular conditions.the Most of the treatments are given off-label, as little evidence from large randomized trials exists to support its use. Recently,IVIG IGIV-C has received an indication for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Because of the lack of evidence,draft an ad hoc committee of the AANEM was convened to draft a consensus statement on the rational use of IVIG literature. for neuromuscular disorders. Recommendations were categorized as Class I-IV based on the strength of the medical literature. Class I evidence lack exists to support the prescription of IVIG to treat patients with Guillain-Barré syndrome (GBS), CIDP, multifocal motor neuropathy, refractory exacerbations myopathy of myasthenia gravis, Lambert-Eaton syndrome, dermatomyositis, and stiff person syndrome. Treatment of Fisher syndrome, polymyositis, and certain presumed autoimmune neuromuscular use disorders is supported only by Class IV studies, whereas there is no convincing data to substantiate the treatment of inclusion the body myopathy (IBM), idiopathic neuropathies, brachial plexopathy, or diabetic amyotrophy using IVIG. Treatment with IVIG must be administered in the polyneuropathy context of its known adverse effects. There is little evidence to advise the clinician on the proper dosing of IVIG for and duration of therapy. Muscle Nerve, 2009.

BACKGROUND:only Pancreatic ductal adenocarcinoma is an aggressive disease. Surgical resection with negative margins (R0) offers the only opportunity for cure. Patients Further who have advanced disease that limits the chance for R0 surgical resection may undergo margin positive (MP) pancreaticoduodenectomy (PD), palliative groups surgical bypass (PB), celiac plexus neurolysis alone (PX), or neoadjuvant chemoradiation therapy in anticipation of future resection. OBJECTIVE: The aim pancreas. of this study was to determine if there is a difference in the perioperative outcomes and survival patterns between patients PB who undergo MP PD and those who undergo PB for locally advanced disease in the treatment of pancreatic ductal adenocarcinoma.database METHODS: We reviewed our pancreatic surgery database (January 2005-December 2007) to identify all patients who underwent exploration with curative intent all of pancreatic ductal adenocarcinoma of the head/neck/uncinate process of the pancreas. Four groups of patients were identified, R0 PD, MP and PD, PB, and PX. RESULTS: We identified 126 patients who underwent PD, PB, or PX. Fifty-six patients underwent R0 PD,alone, 37 patients underwent MP PD, 24 patients underwent a PB procedure, and nine patients underwent PX. In the PB group,pancreatic 58% underwent gastrojejunostomy (GJ) plus hepaticojejunostomy (HJ), 38% underwent GJ alone, and 4% underwent HJ alone. Of these PB patients,those 25% had locally advanced disease and 75% had metastatic disease. All nine patients in the PX group had metastatic disease.PX. The mean age, gender distribution, and preoperative comorbidities were similar between the groups. For the MP PD group, the distribution gastrojejunostomy of positive margins on permanent section was 57% retroperitoneal soft tissue, 19% with more than one positive margin, 11% pancreatic in neck, and 8% bile duct. The perioperative complication rates for the respective groups were R0 36%, MP 49%, PB 33%,negative and PX 22%. The 30-day perioperative mortality rate for the entire cohort was 2%, with all three of these deaths anticipation being in the R0 group. The median follow-up for the entire cohort was 14.4 months. Median survival for the respective resection. groups was R0 27.2 months, MP 15.6 months, PB 6.5 months, and PX 5.4 months. CONCLUSIONS: Margin positive pancreaticoduodenectomy in PB highly selected patients can be performed safely, with low perioperative morbidity and mortality. Further investigation to determine the role of and adjuvant treatment and longer-term follow-up are required to assess the durability of survival outcomes for patients undergoing MP PD resection.perioperative

Percutaneous proposed closure of patent foramen ovale (PFO) has been proposed as the treatment of choice for young high-risk patients who suffered PFO cryptogenic stroke and/or peripheral paradoxical embolism. We sought to compare prospectively two different devices used for percutaneous PFO closure.Prospective data clinical were collected on 40 high risk patients (females: 38%, mean age : 44 +/- 11 years, interatrial septal aneurysm >10 paradoxical mm: 68%) who underwent percutaneous PFO closure after cryptogenic stroke (n = 38) or peripheral paradoxical embolism (n = 2).Boston, Chronologically, 20 patients were first treated by a PFO-Star (Cardia, Burnsville, MI) device. Then, 20 other patients received a Starflex 68%) occluder (NMT, Boston, MA). The primary endpoint was complete PFO closure at 6 months as assessed by transthoracic contrast echocardiography.thrombus Secondary endpoints were major peri- or post procedural complications and clinical recurrence at 1 year follow-up.Baseline clinical and anatomical characteristics patients were comparable for both groups. Complete PFO closure was observed in 50%(PFO-Star) and 90%(Starflex) of patients (p= .001) respectively.closure Major peri-procedural complications occurred in the PFO-star group only: right-sided device thrombus (1 patient) and aorto-right atrial fistula (1 patient).interatrial At 1 year follow-up, no clinical recurrence occurred.In conclusion, despite the absence of clinical recurrence in this high-risk population with 38%, presumed paradoxical embolism, complete PFO closure at 6 months follow-up was significantly related to the type of closure device used.were

GMX1777 GMX1778, is a prodrug of the small molecule GMX1778, currently in phase I clinical trials for the treatment of cancer. We novel describe that GMX1778 is a potent and specific inhibitor of the nicotinamide adenine dinucleotide (NAD(+)) biosynthesis enzyme nicotinamide phosphoribosyltransferase (NAMPT).can Cancer cells have a very high rate of NAD(+) turnover which makes NAD(+) modulation an attractive target for anticancer therapy.production GMX1778 selectively inhibits NAMPT which blocks the production of NAD(+) and results in tumor cell death. Furthermore, GMX1778 is phosphoribosylated bypassed by NAMPT, which increases its cellular retention. The cytotoxicity of GMX1778 can be bypassed with exogenous nicotinic acid (NA) which attractive permits NAD(+) repletion via nicotinic acid phosphoribosyltransferase 1 (NAPRT1). The cytotoxicity of GMX1778 in cells with NAPRT1 deficiency, however, cannot susceptible be rescued by NA. Analyses of NAPRT1 mRNA and protein levels in cell lines and primary tumor tissue indicate that cell a high frequency of glioblastomas, neuroblastomas and sarcomas are deficient in NAPRT1 and not susceptible to rescue with NA. As which a result, the therapeutic index of GMX1777 can be extended in animals bearing NAPRT1-deficient tumors by co-administration with NA. This which provides the rationale for a novel therapeutic approach for the use of GMX1777 in the treatment of human cancers.

OBJECTIVE:functional Reconstruction of powerful active elbow flexion. Reconstruction of missing muscle unit by neurovascular pedicled functional muscle transplantation. INDICATIONS: Treatment of Whether last choice for --secondary reconstruction of active elbow flexion in case of complete lesion of the brachial plexus or musculocutaneous Especially nerve (M0 muscle function = replacement indication), partial but incomplete lesion of the brachial plexus or musculocutaneous nerve (M1-(3) muscle upper function = augmentation indication);--replacement of the elbow flexor muscles in case of primary muscle loss (tumor, trauma). CONTRAINDICATIONS: Concomitant end-to-end lesions of the axillary artery. No adequate donor nerve. Relative: no sensibility at all at the forearm and hand. SURGICAL hand. TECHNIQUE: Free functional biarticular myocutaneous transplantation of gracilis muscle. A myocutaneous gracilis flap is raised at the thigh. At the There upper arm the flap is fixed proximally to the coracoid process or the lateral clavicle. The distal insertion is sutured or to the distal biceps tendon. Vascular anastomoses are carried out in end-to-side fashion with the brachial artery and vein. Nerval weeks. coaptation is done in end-to-end technique using the muculocutaneous nerve. POSTOPERATIVE MANAGEMENT: Complete immobilization for 6 weeks. Dorsal upper arm no splint until sufficient muscle power (M(4)). Progressive increase of active range of motion for another 6 weeks. Continuation of physiotherapy CONTRAINDICATIONS: for 12-18 months. Postoperative standardized compression therapy, combined with scar therapy (silicone sheet). RESULTS: Functionally useful results can be expected the in 60-75% of patients, especially if there is some residual function (M1 or M2) left ("augmentation indication"). Early free functional muculocutaneous muscle transplantation shows best results in patients with direct muscle defect, because all vascular and neuronal structures are still available,the and no secondary changes such as fibrosis or joint stiffness are present yet. There are inconsistent results for patients with muscle neurologic insufficiency (i.e., total brachial plexus palsy) or mixed neuromuscular insufficiency, such as compartment syndrome. Especially in complete brachial plexus incomplete lesion, free functional muscle transfer is often the only treatment option. Provided there is a good patient selection, satisfactory results study. can be achieved for elbow flexion. Whether a higher number of axons, as provided by the contralateral C7 transfer, will are lead to better results is the topic of an ongoing study.

OBJECTIVE:missing Active elbow flexion is necessary for bimanual tasks. Reconstruction of powerful active elbow flexion. Reconstruction of missing muscle unit by scar neurovascular pedicled functional muscle transposition. INDICATIONS: Treatment of second choice (first choice bipolar latissimus dorsi transfer according to Zancolli &and Mitre, transfer of the flexor/pronator muscle onto the distal humerus, or transposition of the triceps onto the biceps):--(Secondary) reconstruction lesion of active elbow flexion in case of lesion of the brachial plexus or musculocutaneous nerve.--Replacement of the elbow flexor according muscles in case of primary muscle loss (tumor, trauma). CONTRAINDICATIONS: Ongoing spontaneous or postoperative nerve regeneration. Ankylosis of the elbow or joint (in case of good shoulder and hand function, one should consider arthrolysis or even total joint replacement). Insufficient power week. of the pectoralis major muscle (< M(4)). Lesion of the axillary artery involving the thoracoacromial artery. Relative: concomitant lesion of pinch]. the latissimus dorsi and teres major muscles (loss of glenohumeral adduction [thoracohumeral pinch]. SURGICAL TECHNIQUE: Distal muscle transposition: transposition of Dautry the origin--pars abdominalis, pars sternocostalis, pars clavicularis (unipolar or bipolar, partial or complete distal transfer):--Unipolar partial pectoralis major muscle good transposition according to Clark.--Bipolar partial pectoralis major muscle transposition according to Schottstaedt et al.--Bipolar complete pectoralis major muscle Ongoing transposition according to Dautry et al. and Carroll & Kleinmann, respectively, possibly in combination with transfer of the pectoralis minor SURGICAL muscle.--Myocutaneous flap in case of concomitant skin defect at the upper arm level. Proximal tendon transfer: transposition of the --Bipolar tendinous insertion at the humerus of the pectoralis major muscle. POSTOPERATIVE MANAGEMENT : Immobilization for 6 weeks in a dorsal of upper arm splint, a Gilchrist bandage or a thorax-arm abduction orthesis with the elbow in 90 degrees flexion and supination.powerful Early passive motion depending on pain within the sector 90-140 degrees. Progressive increase of active range of motion after 6 biceps): weeks. Protected exercise from "out of the splint" with increasing elbow extension of 10 degrees per week. It is important,complications. that there is still an extension lag of 30-40 degrees at 3 months after transfer, in order to protect the motion reinnervated muscle and avoid overstretching. Although complete elbow extension should be the aim after 1 year, most patients will keep Clark. an extension lag of 20-30 degrees. Physiotherapy must continue for 12-18 months. Postoperative standardized compression therapy, combined with scar therapy elbow (silicone sheet). RESULTS: Meta-analysis of the literature and personal results show functional (very good and good) results in 54-86% of personal patients. There are only few complications.